摘要
恶性胸腔积液(MPE)是由恶性肿瘤胸腔转移或原发性胸腔恶性肿瘤所致。MPE形成的分子机制非常复杂,其中血管内皮细胞生成因子(VEGF)发挥了重要的作用。VEGF是重组人血管内皮抑制素(恩度)抗血管生成作用的靶点之一。本文就近年来有关MPE以及恩度治疗MPE的转化、临床研究进展进行综述。
Malignant pleural effusion(MPE)is caused by malignant thoracic metastasis or primary malignant pleural tumors.The molecular mechanism of MPE formation is complex,and vascular endothelial growth factor(VEGF)plays an important role.Vascular growth factor(VEGF)is one of the targets of anti-angiogenesis effect of recombinant human endostatin(Endostar).This article reviews the recent advances in the research of MPE and the transformation and clinical research of Endor in the treatment of MPE.
作者
苗静
秦叔逵
MIAO Jing;QIN Shukui(Graduate School of Nanjing University of Traditional Chinese Medicine,Nanjing 210023,China)
出处
《临床肿瘤学杂志》
CAS
北大核心
2019年第9期850-855,共6页
Chinese Clinical Oncology
